This blog was originally posed on the Dengue Vaccine Initiative website
 
This year’s Americas Dengue Prevention Board (DPB) convened in Mexico City from March 25–26. The meeting’s objective was to assess the feasibility and benefits of integrating dengue vector-control strategies with an upcoming dengue vaccine. DVI compiled a summary of the discussions and recommendations from the Board in a new report you can access here.
 
The meeting brought together vaccine and vector control experts, researchers, representatives of ministries of health and vaccine manufacturers from different countries who brainstormed to answer:
 
Assuming a dengue vaccine is licensed and introduced, how could a country integrate prevention of dengue through a vaccination program with existing or new vector control methodologies?
 
This question is crucial to raise awareness about the urgency of new approaches to fight dengue in light of the recent spike in infections, which shows that vector control, alone, cannot effectively prevent dengue outbreaks. The discussions took into consideration new developments in dengue surveillance, like progress with vaccine candidates, the increasing community engagement in vector control and results from mathematical modeling of the impacts that integrating dengue prevention strategies would have on the dengue’s incidence, to underscore the need to evaluate dengue prevention and control strategies comprehensively and in line with a forthcoming dengue vaccine.
 
“Several novel vector control tools are, or are soon to be, available (new insecticides, genetic and biologic control, spatial repellents and lethal traps) and these hold promise for greater impact on disease transmission. A dengue vaccine is also expected in the coming years. Approaches that integrate both vector control and vaccination hold the best promise for prevention and control."
 
As the report captures, the meeting first evaluated vector control efforts in Latin American countries, including Mexico, Nicaragua, Paraguay, Colombia, Venezuela, Argentina, Costa Rica, Brazil and Puerto Rico. Participants also assessed new technologies and partnerships for vector control, dengue vaccine candidates’ developments, and new mathematical models.  
 
The Board concluded the event by identifying the requirements needed to effectively integrate vaccination and vector control. Some of these requirements consisted of generating baseline data to evaluate the additive effects of a vaccine; strengthening capacity for monitoring and evaluation; and standardizing entomological indicators to ease comparisons between countries. The requirements fall into four main areas of focus as the Board identified during the meeting: (1) criteria for selection of study sited and study design; (2) communication and coordination with other sectors; (3) standardization of entomological surveillance; and (4) development of policies for vector control.  
 
We invite you to read the Board’s recommendations in detail here.  
 
These conversations are critical to generate consensus at all levels about the need for a dengue vaccine. By creating an enabling and participatory communication environment, DVI is working hard to help support the introduction of a future dengue vaccine.
 
About Dengue Prevention Boards
 
In 2007, PDVI (Pediatric Dengue Vaccine Initiative—DVI’s precursor) established two regional DPBs — one for Asia and one for the Americas. Member of the boards include medical and public health experts, opinion leaders and policy makers from countries in their respective regions. They meet once a year to advise on dengue surveillance, diagnostics, vaccine introduction and communications.
 
All reports on DPB meetings are published in the DVI website to inform stakeholders on their content and conclusions and consensus.